Almirall SA
MAD:ALM

Watchlist Manager
Almirall SA Logo
Almirall SA
MAD:ALM
Watchlist
Price: 11.14 EUR 0.18% Market Closed
Market Cap: 2.4B EUR

EV/EBITDA
Enterprise Value to EBITDA

12.7
Current
10.1
Median
12.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
12.7
=
Enterprise Value
2.4B EUR
/
EBITDA
188.7m EUR
Market Cap EV/EBITDA
ES
Almirall SA
MAD:ALM
2.4B EUR 12.7
US
Eli Lilly and Co
NYSE:LLY
751.9B USD 36.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 3 846.3
US
Johnson & Johnson
NYSE:JNJ
375.2B USD 12.6
DK
Novo Nordisk A/S
CSE:NOVO B
2.3T DKK 15.1
CH
Roche Holding AG
SIX:ROG
214.5B CHF 9.7
CH
Novartis AG
SIX:NOVN
190.8B CHF 10.6
UK
AstraZeneca PLC
LSE:AZN
168.5B GBP 131.2
US
Merck & Co Inc
NYSE:MRK
203.6B USD 8.7
IE
Endo International PLC
LSE:0Y5F
163.5B USD 261.3
US
Pfizer Inc
NYSE:PFE
137.8B USD 7.5
EBITDA Growth EV/EBITDA to Growth
ES
Almirall SA
MAD:ALM
Average EV/EBITDA: 395.6
12.7
19%
0.7
US
Eli Lilly and Co
NYSE:LLY
36.3
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
15.1
13%
1.2
CH
Roche Holding AG
SIX:ROG
9.7
5%
1.9
CH
Novartis AG
SIX:NOVN
10.6
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
131.2
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.7
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
2%
3.8

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
10.6
2-Years Forward
EV/EBITDA
8.7
3-Years Forward
EV/EBITDA
7.5